Nobody dares stopping clinical research, not even COVID-19

In the global health emergency caused by the COVID-19, clinical trial management has proven to be critical for the pharmaceutical industry, sponsors, and healthcare professionals. Our experience as a sponsor managing interventional oncology clinical studies has provided us with some data and insight...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Andrea Malfettone, Serena Di Cosimo, José Manuel Pérez-García, Alicia García, Miguel Sampayo-Cordero, Leonardo Mina, Carolina Herrero, Antonio Llombart-Cussac, Javier Cortés
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/33b48eb9a9dd438c9f6dd121fdf66906
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:33b48eb9a9dd438c9f6dd121fdf66906
record_format	dspace
spelling	oai:doaj.org-article:33b48eb9a9dd438c9f6dd121fdf669062021-12-02T14:37:36ZNobody dares stopping clinical research, not even COVID-1910.1038/s41523-021-00249-12374-4677https://doaj.org/article/33b48eb9a9dd438c9f6dd121fdf669062021-04-01T00:00:00Zhttps://doi.org/10.1038/s41523-021-00249-1https://doaj.org/toc/2374-4677In the global health emergency caused by the COVID-19, clinical trial management has proven to be critical for the pharmaceutical industry, sponsors, and healthcare professionals. Our experience as a sponsor managing interventional oncology clinical studies has provided us with some data and insights. Though limited by sample size, our data emphasize the importance of quickly adopting measures that first prioritize patient safety and data validity, then consider contingency measures such as telemedicine, virtual medical review, and remote monitoring. Successful adaptations of healthcare and patient management in response to COVID-19 have been fundamental to ensuring continuing clinical cancer research.Andrea MalfettoneSerena Di CosimoJosé Manuel Pérez-GarcíaAlicia GarcíaMiguel Sampayo-CorderoLeonardo MinaCarolina HerreroAntonio Llombart-CussacJavier CortésNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Breast Cancer, Vol 7, Iss 1, Pp 1-3 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Andrea Malfettone Serena Di Cosimo José Manuel Pérez-García Alicia García Miguel Sampayo-Cordero Leonardo Mina Carolina Herrero Antonio Llombart-Cussac Javier Cortés Nobody dares stopping clinical research, not even COVID-19
description	In the global health emergency caused by the COVID-19, clinical trial management has proven to be critical for the pharmaceutical industry, sponsors, and healthcare professionals. Our experience as a sponsor managing interventional oncology clinical studies has provided us with some data and insights. Though limited by sample size, our data emphasize the importance of quickly adopting measures that first prioritize patient safety and data validity, then consider contingency measures such as telemedicine, virtual medical review, and remote monitoring. Successful adaptations of healthcare and patient management in response to COVID-19 have been fundamental to ensuring continuing clinical cancer research.
format	article
author	Andrea Malfettone Serena Di Cosimo José Manuel Pérez-García Alicia García Miguel Sampayo-Cordero Leonardo Mina Carolina Herrero Antonio Llombart-Cussac Javier Cortés
author_facet	Andrea Malfettone Serena Di Cosimo José Manuel Pérez-García Alicia García Miguel Sampayo-Cordero Leonardo Mina Carolina Herrero Antonio Llombart-Cussac Javier Cortés
author_sort	Andrea Malfettone
title	Nobody dares stopping clinical research, not even COVID-19
title_short	Nobody dares stopping clinical research, not even COVID-19
title_full	Nobody dares stopping clinical research, not even COVID-19
title_fullStr	Nobody dares stopping clinical research, not even COVID-19
title_full_unstemmed	Nobody dares stopping clinical research, not even COVID-19
title_sort	nobody dares stopping clinical research, not even covid-19
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/33b48eb9a9dd438c9f6dd121fdf66906
work_keys_str_mv	AT andreamalfettone nobodydaresstoppingclinicalresearchnotevencovid19 AT serenadicosimo nobodydaresstoppingclinicalresearchnotevencovid19 AT josemanuelperezgarcia nobodydaresstoppingclinicalresearchnotevencovid19 AT aliciagarcia nobodydaresstoppingclinicalresearchnotevencovid19 AT miguelsampayocordero nobodydaresstoppingclinicalresearchnotevencovid19 AT leonardomina nobodydaresstoppingclinicalresearchnotevencovid19 AT carolinaherrero nobodydaresstoppingclinicalresearchnotevencovid19 AT antoniollombartcussac nobodydaresstoppingclinicalresearchnotevencovid19 AT javiercortes nobodydaresstoppingclinicalresearchnotevencovid19
_version_	1718391000201691136

Nobody dares stopping clinical research, not even COVID-19

Ejemplares similares